DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novartis Pharma AG

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

94 Comunicados de prensa

Ver todos los comunicados de prensa
30/04/2026
Farmacéutica
Anuncios breves
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
27/04/2026
Farmacéutica
Anuncios breves
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
26/04/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
24/04/2026
Farmacéutica
Anuncios breves
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
23/04/2026
Farmacéutica
Anuncios breves
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
08/04/2026
Farmacéutica
Anuncios breves
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
28/03/2026
Farmacéutica
Anuncios breves
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
26/03/2026
Farmacéutica
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
22/03/2026
Farmacéutica
Anuncios breves
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
19/03/2026
Farmacéutica
Anuncios breves
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0